Cargando…
Bacteroides Fragilis Polysaccharide A Ameliorates Abnormal Voriconazole Metabolism Accompanied With the Inhibition of TLR4/NF-κB Pathway
The antifungal agent voriconazole (VRC) exhibits extreme inter-individual and intra-individual variation in terms of its clinical efficacy and toxicity. Inflammation, as reflected by C-reactive protein (CRP) concentrations, significantly affects the metabolic ratio and trough concentrations of voric...
Autores principales: | Wang, Xiaokang, Ye, Chunxiao, Xun, Tianrong, Mo, Liqian, Tong, Yong, Ni, Wensi, Huang, Suping, Liu, Bin, Zhan, Xia, Yang, Xixiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115215/ https://www.ncbi.nlm.nih.gov/pubmed/33995087 http://dx.doi.org/10.3389/fphar.2021.663325 |
Ejemplares similares
-
Cellular immunity to Bacteroides fragilis capsular polysaccharide
Publicado: (1982) -
The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice
por: Zhou, Wei, et al.
Publicado: (2022) -
Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections
por: Xun, Tianrong, et al.
Publicado: (2023) -
Interaction of Bacteroides fragilis and Bacteroides thetaiotaomicron with the kallikrein–kinin system
por: Murphy, Elizabeth C., et al.
Publicado: (2011) -
Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
por: Zheng, Lijun, et al.
Publicado: (2020)